VIM and lung cancer: Lennon et al. [57] demonstrated that STAT3 inhibitor Stattic decreased the opioid and EGF-induced human lung cancer cell proliferation, migration, and EMT transformation (as determined by loss of mesenchymal proteins such as vimentin and the acquisition of epithelial markers including claudin-1).